JMIR Diabetes最新文献

Unlabelled: Clinics continue to adopt care models shaped by the algorithmic analysis of continuous glucose monitoring (CGM) data, such as remote patient monitoring for type 1 diabetes. No clinic-facing quantitative framework currently exists to track the impact of such algorithm-directed care on patient outcomes and clinical workload. We used CGM data from the Teamwork, Targets, Technology, and Tight Control (4T) Study (Pilot n=135 and Study 1 n=133), in which algorithms enable precision, whole-population care by directing clinician attention to patients with deteriorating glucose management. Youth meeting criteria for clinical review are then contacted by Certified Diabetes Care and Education Specialists. Through iterative data analysis and meetings with a variety of stakeholders, we identified metrics for reviewing and revising clinical workloads, glucose management, and timeliness of care. For each metric, we developed an interactive dashboard to provide clinical and administrative leaders with an overview of the program. The metrics to track clinical workload were the total number of youths (1) in the program, (2) in each study, and (3) cared for by each clinician. The metrics to track glucose management were the number of youths meeting each criterion for review, including (4) total, (5) for each clinician, and (6) for each study. The metric to track timeliness of care was (7) the number of days since meeting criteria for clinical review. When presented at regular program leadership meetings, the metrics facilitated data-driven decision-making about clinical and operational components of the program. In this paper, we describe the process of developing and operationalizing this reproducible, clinician-facing key performance indicator tool to monitor an algorithm-enabled remote patient monitoring program. As the role of algorithms grows in directing clinical effort and prioritizing patients for care, this framework may help clinics track clinical workload, patient outcomes, and the timeliness of care.

Unlabelled: For adults living with type 1 diabetes (T1D), diabetes-specific mental health support is limited. Peer support and digital health platforms are promising strategies for delivering this support to this population, particularly those from geographically marginalized communities. Mobile apps, in particular, can enhance self-management and deliver support. This paper describes the iterative co-design and development process of a novel mobile app for use in a pilot trial, T1D REACHOUT (REACHOUT), that aims to reduce the diabetes distress, a core facet of diabetes-specific mental health, of adults with T1D. An initial think tank and 6 focus groups were conducted with adults with T1D to better understand their support needs and identify platform requirements. Following this, we partnered with adults living with T1D, the "end users," to iteratively co-design the REACHOUT app, enhancing usability and ensuring relevance. Adapting the open-source Rocket.Chat platform to user-defined requirements, we deployed the app in a single cohort pilot study. A network analysis of messages exchanged during the pilot study was performed to explore trends and patterns and demonstrate implementation feasibility. Pilot study outcomes informed further refinement before implementation in a randomized controlled trial. The implementation of the REACHOUT app features 6 key components identified in 6 initial focus groups: a 24/7 chatroom (a customized group messaging function with threads), topic-specific discussion boards, a peer supporter library, peer supporter profiles for a user-driven matching process, small group virtual sessions, and direct (one-to-one) messaging. Forty-six participants were encouraged to use any or all of the features as frequently as desired over a 6-month period during the pilot study. During this time, 179 private small groups were created, and 10,410 messages were sent, including 1389 chat room messages and 7116 direct messages; among these were 3446 messages exchanged between participants and their self-selected peer supporters. Key factors for successful implementation included (1) the co-design process involving comprehensive user engagement and (2) the opportunities realized through hybrid development. These findings offer generalizable lessons for mobile health research teams developing similar app-based interventions.

Background: Patients with diabetes carry a 1.5- to 2-fold higher risk of community-acquired pneumonia (CAP) and experience more severe outcomes, yet the mechanisms that integrate metabolic dysregulation, pathogen shifts, and novel cell death pathways remain fragmented.

Objective: This study aimed to synthesize current evidence on epidemiology, pathophysiology, causative pathogens, clinical outcomes, and management of CAP in adults with diabetes and to identify research gaps for future trials.

Methods: A narrative review (1999 to August 2025) of PubMed, EMBASE, the Cochrane Library, and Web of Science was conducted. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to rate evidence from 81 selected English-language studies (randomized controlled trials, cohorts, and meta-analyses).

Results: Diabetes increases CAP incidence (relative risk 1.73, 95% CI 1.46-2.04), hospitalization (+30%-50%), and 30-day mortality (odds ratio 1.67, 95 % CI 1.45-1.92). Key drivers include hyperglycemia-induced immune paralysis, pulmonary microangiopathy, ferroptosis, glycation and methylation changes, and gut-lung dysbiosis that collectively favor multidrug-resistant Gram-negative bacilli (Klebsiella and Pseudomonas) and severe viral and fungal coinfections. Host-targeted therapy with moderate glycemic control (5-10 mmol/L), continued metformin, and pathogen-directed antibiotics improves survival, whereas single-dose PCV20 and annual influenza vaccination prevents approximately 45% of CAP admissions. Emerging strategies (nanozymes, ferroptosis inhibitors, probiotics, and proteolysis-targeting chimeras) are still preclinical.

Conclusions: CAP in patients with diabetes is a distinct, more severe entity mediated by metabolic-immune crosstalk. Multicenter randomized controlled trials integrating tight glucose monitoring, novel host-directed agents, and microbiome modulation are warranted to translate mechanistic insights into better outcomes.

Background: The 75-g oral glucose tolerance test (OGTT) remains the optimal diagnostic test for use in pregnancy but needs to be performed in the clinical setting. The GTT@home OGTT device offers the potential to enable patients to perform the test at home using capillary blood samples.

Objective: This study aimed to determine the accuracy of the GTT@home device compared to the routine National Health Service laboratory reference method using blood samples during an OGTT from pregnant women at high risk of developing gestational diabetes mellitus (GDM).

Methods: A total of 65 women (aged >18 y), at high risk for GDM (per the National Institute for Health and Care Excellence guidelines) were recruited for this performance evaluation. Following an overnight fast, participants went for a 75-g OGTT. Fasting and 2-hour capillary glucose levels were measured using the GTT@home device with corresponding venous samples measured in the laboratory.

Results: The complete data for analysis was available for 61/65 devices. The overall bias for the GTT@home device was +0.16 mmol/L. Correlation analysis of the clinical performance of the two methods using a surveillance error grid showed 79.8% of results in the lowest, 16.9% in the "slight, lower" and 2.4% in the "slight, higher" risk categories. Only 0.8% were "moderate, lower" risk, and none were in any higher risk categories. There was agreement in the classification in 54/61 cases. The GTT@home device under-classified 2 cases and over-classified 5 cases.

Conclusions: The GTT@home device worked well in a controlled, antenatal clinical setting. Differences in classification observed were generally due to small differences in glucose values close to the diagnostic cut-offs. The GTT@home device shows promise for home testing of glucose tolerance in pregnant women.

Background: Older adults with diabetes frequently access their electronic health record (EHR) notes but often report difficulty understanding medical jargon and nonspecific self-care instructions. To address this communication gap, we developed Support-Engage-Empower-Diabetes (SEE-Diabetes), a patient-centered, EHR-integrated diabetes self-management support tool designed to embed tailored educational statements within the assessment and plan section of clinical notes.

Objective: This study aimed to validate the clarity, relevance, and alignment of SEE-Diabetes content with the Association of Diabetes Care & Education Specialists 7 Self-Care Behaviors framework from the perspectives of older adults and clinicians.

Methods: An interdisciplinary team conducted expert reviews and qualitative interviews with 11 older adults with diabetes and 8 clinicians practicing in primary care (family medicine) and specialty diabetes care settings at a Midwestern academic health center. Patients evaluated the readability and relevance of the content, while clinicians assessed clarity, sufficiency, and potential clinical utility. Interview data were analyzed using inductive thematic analysis, and descriptive statistics were used to summarize participant characteristics.

Results: Patients (mean age 72, SD 4.9 y; mean diabetes duration 26, SD 15 y) reported that the SEE-Diabetes statements were clear, relevant, and written in plain language that supported understanding of self-care recommendations. Clinicians (mean 13, SD 9.5 y of diabetes care experience) viewed the content as concise, clinically appropriate, and well aligned with patient self-management goals and the Association of Diabetes Care & Education Specialists 7 Self-Care Behaviors framework. Both groups identified the tool's potential to enhance patient engagement and patient-clinician communication, while noting opportunities to improve the specificity of language, particularly within medication-related content.

Conclusions: SEE-Diabetes demonstrated content validity as a practical, patient-centered digital health tool for supporting diabetes self-management communication within EHR clinical notes. The findings support its use as a complementary approach to reinforce self-care communication in routine clinical practice and highlight areas for refinement to enhance personalization.